People who suffer from chronic sinusitis often experience nasal polyps. Nasal polyps are inflammatory, non-cancerous growths along the lining of the nasal passages that can obstruct the flow of air as well as cause congestion, nasal discharge, facial pain and a loss of smell.
For the more than 500,000 people in the U.S. who undergo endoscopic sinus surgery each year for the treatment of chronic sinusitis, as many as 60% of patients experience a recurrence of nasal polyps.
Mid-Kansas Ear, Nose and Throat is pleased to offer SINUVA¹, a cutting-edge, non-surgical treatment for nasal polyps in adults who have had previous ethmoid sinus surgery (ESS). SINUVA (mometasone furoate) is designed to reduce nasal congestion, obstruction and polyps.²
SINUVA is an implant placed into the nasal opening during a routine physician office visit. The implant expands, delivering an anti-inflammatory medicine directly into the sinus cavity for up to 90 days. The implant then softens over time and may be expelled out of the nose on its own, or through sneezing or nose blowing. It can be removed at 90 days or earlier at the doctor’s discretion.
To see how SINUVA works, visit https://www.sinuva.com/what-is-sinuva/.
¹SINUVA is FDA-approved for patients over the age of 18 who have had previous ethmoid sinus surgery and suffer from recurrent nasal polyps. The area around SINUVA should be monitored by a physician for any signs of bleeding, irritation, infection or perforation. For full safety info, visit www.SINUVA.com.
²Data on file, Intersect ENT. RESOLVE II CSR R 28017 Rev. 3.0 February 2017.